Apple (AAPL) Marches Higher; Investors Looking for Positive Outcome in Samsung Trial
Tweet Send to a FriendGet Alerts AAPL Hot Sheet
Price: $433.26 -0.3%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +11.2%
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.7%
Revenue Growth %: +11.2%
Trade AAPL Now!
Are Apple Inc. (Nasdaq: AAPL) investors already pricing in a strong outcome in litigation with Samsung?
Shares of Apple are up just under 1 percent in early trading Monday, hitting another all-time high of $655 in the process, amid reports CEO Tim Cook and Samsung CEO Kwon Oh Hyun will hold a call today to see if the two can enter a patent settlement before jury deliberations commence on Tuesday. Results of the call will be reported later in the session.
In the case, Samsung is seeking $399 million in damages along with devices being banned, while Apple said it lost $2.5 billion to $2.75 billion in sales.
Apple has closed higher nine of the last 12 sessions.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of Apple are up just under 1 percent in early trading Monday, hitting another all-time high of $655 in the process, amid reports CEO Tim Cook and Samsung CEO Kwon Oh Hyun will hold a call today to see if the two can enter a patent settlement before jury deliberations commence on Tuesday. Results of the call will be reported later in the session.
In the case, Samsung is seeking $399 million in damages along with devices being banned, while Apple said it lost $2.5 billion to $2.75 billion in sales.
Apple has closed higher nine of the last 12 sessions.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Apple (AAPL) Streaming Music Service Could be Delayed - The Verge
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- UPDATE: Student Loan Rates Set for Change; ITT (ESI) & Corinthian (COCO) on Move
Create E-mail Alert Related Categories
Insiders' Blog, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
